## CONTENT

### Introduction

Ch. 1: Introduction and outline of this thesis 9

### Diagnostics & response prediction

Ch. 2: Non-classic *EGFR*-mutations in a cohort of Dutch *EGFR*-mutated NSCLC-patients and outcomes following EGFR-TKI treatment *Accepted for publication in British Journal of Cancer* 29

Ch. 3: Incidence of T790M mutation in (sequential) rebiopsies in *EGFR*-mutated NSCLC-patients *Lung Cancer* 2014 Jul;85(1):19-24 51

Ch. 4: Ch. 4a: Detecting resistance in *EGFR*-mutated NSCLC after clonal selection through targeted therapy *Personalized Medicine* 2015 Apr;12(2): 63-6 69

Ch. 4b: Transformation to a squamous cell carcinoma phenotype of an *EGFR*-mutated NSCLC-patient after treatment with an *EGFR*-tyrosine kinase inhibitor *Journal of Clinical Pathology* 2015 Apr;68(4):320-1 75

Ch. 5: VeriStrat® has prognostic value in advanced stage NSCLC-patients treated with erlotinib and sorafenib *British Journal of Cancer* 2012 Nov 20;107(11):1820-5 81

### Treatment

Ch. 6: Challenges in the management of *EGFR*-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors *Oncology* 2014;87(2):83-94 97

Ch. 7: Treatment and survival of patients with *EGFR*-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis *Lung Cancer* 2015 Sep;89(3):255-61 115

Ch. 8: Ch. 8a: High-dose, pulsatile erlotinib in two NSCLC-patients with leptomeningeal metastases – one with a remarkable thoracic response as well *Lung Cancer* 2013 Apr;80(1):102-5 131

Ch. 8b: High-dose, weekly erlotinib is not an effective treatment in *EGFR*-mutated non-small cell lung cancer patients with acquired extracranial progressive disease on standard dose erlotinib *Adapted from: European Journal of Cancer* 2014 May;50(7):1399-401 139
Ch. 9: Outcome on afatinib in NSCLC-patients who progressed on prior treatment with erlotinib or gefitinib

In progress

Discussion

Ch. 10: Ch. 10a: Summary and future perspectives 165
Ch. 10b: Dutch summary (Nederlandse samenvatting) 177

Curriculum Vitae 187
Dankwoord 189
List of publications 195